63 related articles for article (PubMed ID: 1685015)
1. [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome].
Zironi C; Pantaleoni M; Zizzo G; Coletta F; Velardo A
Minerva Ginecol; 1991 Oct; 43(10):443-7. PubMed ID: 1685015
[TBL] [Abstract][Full Text] [Related]
2. Evidence of altered dopaminergic modulation of prolactin and thyrotropin secretion in patients with polycystic ovary syndrome.
Velardo A; Pantaleoni M; Zironi C; Zizzo G; Marrama P
Horm Res; 1991; 35(1):4-7. PubMed ID: 1916652
[TBL] [Abstract][Full Text] [Related]
3. [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome].
Wu X; Gu Q; Su Y
Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):489-91. PubMed ID: 9639745
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
6. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
[TBL] [Abstract][Full Text] [Related]
7. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
8. Prolactin levels in the polycystic ovary syndrome.
Milewicz A
J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
[TBL] [Abstract][Full Text] [Related]
9. Primary amenorrhoea associated with polycystic ovarian syndrome.
Valkov IM; Dokumov SI
Reproduccion; 1981; 5(2):119-26. PubMed ID: 6790313
[TBL] [Abstract][Full Text] [Related]
10. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome.
Cho LW; Jayagopal V; Kilpatrick ES; Holding S; Atkin SL
Ann Clin Biochem; 2006 May; 43(Pt 3):217-9. PubMed ID: 16704758
[TBL] [Abstract][Full Text] [Related]
11. Increased prolactin response to thyrotropin-releasing hormone in primary ovarian failure.
Hochner-Celnikier D; Zylber-Haran E; Shilo S; Palti Z; Spitz IM
Obstet Gynecol; 1982 Mar; 59(3):280-4. PubMed ID: 6804899
[TBL] [Abstract][Full Text] [Related]
12. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
13. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.
Uncu G; Sözer MC; Develioğlu O; Cengiz C
Gynecol Endocrinol; 2002 Dec; 16(6):447-52. PubMed ID: 12626031
[TBL] [Abstract][Full Text] [Related]
14. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
[TBL] [Abstract][Full Text] [Related]
15. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
[TBL] [Abstract][Full Text] [Related]
16. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
McCartney CR; Eagleson CA; Marshall JC
Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
18. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
[TBL] [Abstract][Full Text] [Related]
19. Evening not morning plasma cortisol level is higher in women with polycystic ovary syndrome.
Kiałka M; Ociepka A; Milewicz T; Krzyczkowska-Sendrakowska M; Gosztyła K; Stochmal E; Lurzyńska M; Bałajewicz-Nowak M
Przegl Lek; 2015; 72(5):240-2. PubMed ID: 26817325
[TBL] [Abstract][Full Text] [Related]
20. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
